Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue 
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Boryung Pharmaceutical has added Eli Lily's Gemzar among the anti-cancer drugs that it has rights to distribute in South Korea.
Boryung also has distribution rights to such anti-cancer drugs as Oxalitin (oxaliplatin) and Genexol (paclitaxel).
Boryung CEO Ahn Jae-hyun promised to continue growing its anti-cancer portfolio as the company's focal point.
Gemzar (gemcitabine), a nucleoside metabolic inhibitor, is mainly a pancreatic cancer treatment drug.
Combined with other drugs, Gemzar is used for the treatment of metastatic breast cancer, advanced ovarian cancer, and non-small cell lung cancer.
Gemzar posted 14.2 billion won in revenue in South Korea last year.
